Publications by authors named "O Rouviere"
Article Synopsis
- The study aimed to create and evaluate a deep learning algorithm for automatically segmenting kidneys and renal cysts in patients with autosomal dominant polycystic kidney disease (ADPKD) using MRI scans.
- Researchers used a combination of historical MRI data and added normal renal scans to train the algorithm, comparing its results to those from human raters to measure accuracy.
- While the algorithm performed fairly well within the variability of human ratings, it tended to underestimate the total kidney and cyst volume, particularly in cases with very large cyst volumes.
Article Synopsis
- Biparametric MRI (bpMRI) may serve as a valid alternative to multiparametric MRI (mpMRI) for diagnosing clinically significant prostate cancer (csPCa), as assessed in a large international observer study.
- The study involved 400 mpMRI examinations from four different European centers, where readers evaluated both bpMRI and mpMRI for their ability to accurately diagnose csPCa, finding them to be similarly effective.
- Key findings indicated that bpMRI and mpMRI had comparable diagnostic accuracy (AUROC values) and sensitivity, with bpMRI showing a noninferior performance, though both methods had similar specificity when distinguishing csPCa.
Article Synopsis
- A carotid web (CaWeb) is a rare fibrous tissue growth in the carotid bulb, often leading to ischemic strokes in younger individuals, especially young women.
- Recent reviews reveal that traditional diagnostic criteria may miss CaWebs since many patients show less than 50% stenosis on ultrasound, complicating their detection and management.
- Current treatment approaches for symptomatic CaWebs focus on procedures like endarterectomy or stenting, but there are still no standardized guidelines for handling asymptomatic cases, making ongoing research crucial.
Background And Objective: Recommendations of first-line therapies for metastatic hormone-sensitive (mHSPC), nonmetastatic castrate-resistant (M0CRPC), and metastatic castrate-resistant (mCRPC) prostate cancer do not account for cardiotoxicity due to a lack of clear prior evidence. This manuscript assesses cardiotoxicity of these therapies.
Methods: We searched Ovid Medline, Elsevier Embase, and the Cochrane Library for randomized clinical trials (RCTs) from database inception to January 14, 2024.